These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 31914241)

  • 1. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
    N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
    Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
    N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
    Della Porta MG; Garcia-Manero G; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcárcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Pilot R; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Prebet T; Lai Y; Degulys A; Paolini S; Cluzeau T; Fenaux P; Platzbecker U
    Lancet Haematol; 2024 Sep; 11(9):e646-e658. PubMed ID: 39038479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
    Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C; Syed YY
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
    Molica M; Rossi M
    Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept: First Approval.
    Markham A
    Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
    Chen N; Kassir N; Laadem A; Maxwell SE; Sriraman P; Giuseppi AC; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):395-404. PubMed ID: 32602651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
    Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
    J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
    Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
    Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
    Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O; Komrokji RS
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Komrokji R; Steensma D; Balleari E; Götze KS; Kotsianidis I; Guerci-Bresler A; Stamatoullas A; Sanz GF; Germing U; Fenaux P
    Leuk Res; 2020 Dec; 99():106472. PubMed ID: 33212326
    [No Abstract]   [Full Text] [Related]  

  • 16. Luspatercept for the treatment of congenital sideroblastic anemia: Two case reports.
    Shao Y; He L; Ding S; Fu R
    Curr Res Transl Med; 2024 Mar; 72(1):103438. PubMed ID: 38244303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
    Garcia-Manero G; Mufti GJ; Fenaux P; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Ilhan O; Sekeres MA; Zeidan AM; Ito R; Zhang J; Rampersad A; Sinsimer D; Backstrom JT; Platzbecker U; Komrokji RS
    Blood; 2022 Jan; 139(4):624-629. PubMed ID: 34758066
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 19. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
    Feld J; Navada SC; Silverman LR
    Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
    Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
    Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.